Beta-blockers are not very effective at lowering blood pressure in elderly hypertensive patients or in AfroCaribbeans and these two groups represent a large proportion of people with raised blood pressure. Furthermore they do not prevent more heart attacks than the thiazide diuretics. Beta-blockers can also be dangerous in many hypertensive patients and even when these drugs are not contraindicated, they cause subtle and depressing side effects which should preclude their usefulness. The time has come therefore to reconsider
Introduction
Beta-adrenergic blockers were first introduced in the early 1960s for the treatment of angina pectoris. Their antihypertensive properties were not fully recognised until the celebrated paper by Pritchard and Gillam in 1964. 1 They rapidly became popular because they had fewer side effects than the older medications like methyldopa, guanethidine, detrisoquine and bethanidine which were available at the time. Beta-blockers were used in several of the longterm morbidity and mortality trials in the treatment of hypertension, either alone or in comparison with the thiazide diuretics. Despite their poor showing in these trials, the guidelines committee of the British Hypertension Society and the sixth American Joint National Committee have taken the view that betablockers, along with thiazides, are the preferred option in the first line treatment of hypertension unless they are specifically contraindicated. 2, 3 Over the last 15 years several new classes of hypertensive drugs have become available which are also effective at lowering blood pressure and more recently the angiotensin receptor antagonists have been found to be almost devoid of side effects.
As the various national and international guidelines committees deliberate on their next set of recommendations there is now a good case for withdrawing any endorsement of the beta-blockers as either first or even second line antihypertensive drugs.
Correspondence: Professor DG Beevers the endorsement of beta-blockers by the British Hypertension Society and other guidelines committees, except possibly for severe resistant hypertension, high risk post-infarct patients and those with angina pectoris. The time has come to move across to newer, safer, more tolerable and more effective antihypertensive agents whilst continuing to use thiazide diuretics in low doses in the elderly as first choice, providing there are no contraindications.
Safety and tolerability
There is little doubt that the beta-blockers are the most unsafe of all antihypertensive drugs. They can precipitate or worsen heart failure in patients with myocardial damage and they are contraindicated in patients with asthma. It is not uncommon for patients to be admitted to hospital with either of these conditions having being rendered acutely unwell by the introduction of a beta-blocker for the treatment of their hypertension. These drugs also worsen Raynaud's phenomenon and intermittent claudication and even peripheral gangrene has been reported. 4 The other problem with the beta-blockers have been their more subtle side effects on exercise tolerance, sleep patterns and the capacity to concentrate. 5 Tiredness and lethargy are unacceptable side effects in previously symptomless mild hypertensives who need to take antihypertensive drugs for the rest of their lives. Furthermore the beta-blockers have been shown to cause impotence. 5 Perhaps the acid test of whether these side effects are acceptable is to ask a group of clinicians whether they themselves would choose to take a beta-blocker if they had uncomplicated mild hypertension. Very few would say 'yes'. Why then do they prescribe them for their patients?
It is probably true that the hydrophilic beta-blockers like atenolol and bisoprolol have fewer side effects and it is also true that many beta-blockers are often being used at unnecessary high doses. However, even when atenolol is prescribed at the dose of 50 mg daily, side effects still occur.
Antihypertensive efficacy
In young hypertensive patients the beta-blockers are not more effective than the other antihypertensive drugs and therefore have no particular advantages. In older patients however, there is good evidence that beta-blockers are less effective than other drugs. In the MRC trial of mild hypertension in the elderly, 7 the Coope and Warrender study 8 and the Swedish Trial of Old Persons (STOP), 9 mildly hypertensive patients were given beta-blockers as their first-line antihypertensive agent. In the majority it proved necessary to add in a thiazide diuretic (Table 1 ). By contrast in the patients in the MRC trial who received a diuretic as first-line therapy and participants in the European Working Party on Hypertension in the Elderly (EWPHE) trial, where thiazide diuretics were also used as first-line therapy, add-in drugs were only necessary in a minority of patients. 10 In the treatment of isolated systolic hypertension, Avanzini et al 11 found that atenolol when used alone produced a good antihypertensive effect in less than 20% of patients whilst diuretics controlled blood pressure in almost half of the patients. This latter figure is similar to that obtained with diuretics in the Systolic Hypertension in the Elderly Programme (SHEP). 12 As hypertension, and particularly isolated systolic hypertension, are largely diseases of the elderly and beta-blockers are barely effective in these patients, there is a very good reason for not using them at all. More sensible drugs to use are the thiazide diuretics or the calcium channel blockers. A survey of general practitioner prescribing habits in elderly patients has shown that the thiazides are the most popular option.
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African origin patients
Several studies in the United States of America have demonstrated that beta-blockers are not very effective in patients of African origin. 14 As hypertension is about twice as common in black people than in whites and again bearing in mind most hypertensives are elderly there is a very good reason for never employing beta-blockers in black patients. Again more sensible drugs are the thiazide diuretics or the calcium channel blockers.
This poor response to beta-blockers is related to the finding that these drugs tend to be less effective in people with low plasma renin levels and an impaired response of renin to sodium depletion. Elderly patients have low plasma renin levels, possibly due to early nephrosclerosis and black patients have low renin levels possibly related to reduced beta-adrenergic responsiveness, exaggerated nephrosclerosis or differences in sodium handling. 15, 16 Whatever the mechanisms, these age and ethnic differences in antihypertensive drug efficacy are well recognised and not controversial.
Beta-blockers as second line therapy
Whilst the beta-blockers are logical add-in drugs in patients who are already receiving either a thiazide diuretic or a calcium channel blocker, they provide little benefit when added to an angiotensinconverting enzyme (ACE) inhibitor or an angiotensin receptor antagonist. 17 As these drugs effectively block the renin-angiotensin system there seems little point in further blocking it by giving beta-blockers as there is no convincing evidence of genuine synergy.
Long term outcome trials of cardiovascular mortality and morbidity
The beta-blockers have been compared with the thiazide diuretics to investigate their capacity to prevent heart attacks and strokes in four studies, two of which were organised by the Medical Research Council. 7, [18] [19] [20] In the MRC studies the beta-blockers had no significant impact overall on the prevention of coronary heart disease and had less impact on the stroke than the thiazide diuretics (Table 2 ). It was suggested that a subgroup of patients in the MRC trial in younger patients, who were non-smokers, might have benefited from beta-blockade but this subgroup analyses itself must be treated with considerable caution. 20 A similar trend was found in the IPPPSH study 18 but no such trend was found in either the HAPPHY study 19 or its subgroup, the MAPHY study. 21 Indeed in this latter study, betablockers appeared to be more effective in preventing heart attacks in smokers. By sharp contrast in the SHEP 10 and the EWPHE 12 studies where thiazide diuretics were used as first-line therapy, coronary prevention rates were impressive. In the Coope and Warrender 8 study where beta-blockers were used, the reduction of coronary heart disease was smaller than in all the other elderly hypertension trials. Beta-blockers therefore do no prevent heart attacks and barely prevent strokes in hypertensive patients.
Post infarction studies
Several studies have shown that beta-blockade is effective at the secondary prevention of myocardial infarction in high risk patients. 22 Despite this only a minority of patients with myocardial infarction are sent home on these agents. 23 In a recent audit of post infarct patients at the City Hospital, Birmingham, we found that only 41% of post infarct patients were sent home taking a beta-blocker despite the absence of any contraindications. There was a slight trend for the cardiologists to use beta-blockers less fre- quently than the general physicians. The reasons for this are uncertain but in a further 41% of cases the non-use of beta-blockade was due to contraindications including heart failure, heart block or asthma. Post infarct patient do have considerable morbidity related to depression following their heart attack and beta-blockers, by causing lethargy, tiredness, sleep disturbance and impaired mentation, must be regarded as an unattractive option. Their use is however justified if the patient is at high risk or suffers from angina pectoris.
Conclusions
The beta-blocking drugs are less effective than other agents in the majority of hypertensive patients and they do not prevent myocardial infarction. They are contraindicated in a large number of people and frequently cause subtle but unpleasant side effects. In particular they can impair the quality of life of hypertensive patients who are usually symptomless until their doctor gives them treatment. It would appear that the Emperor has no clothes! With the advent of the ACE inhibitors, the newer calcium channel blockers and now the angiotensin receptor antagonists, the clinician can use drugs which do not cause these subtle and depressing side effects. These drugs must surely now be the preferred option. In view of the above information, the guideline committees of the British Hypertension Society and the American Joint National Committee should seriously reconsider whether beta-blockers have any role in the treatment of hypertension, except possibly as a third line add-on drug in patients whose blood pressures remain uncontrolled despite the combination of either an ACE inhibitor or an angiotensin receptor antagonist with either a calcium channel blocker or a thiazide diuretic. Their continued use in patients with coronary heart disease can only be justified in very high risk patients or those with persistent angina.
Postscript
It is of interest that since this review was written, and rejected by the British Medical Journal, an overview analysis by Professor Franz Messerli and colleagues has broadly come to the same conclusion. 24 Neither of us were aware of the others work or opinions on the role of beta-blockers in hypertension.
